SEC Form 4 · accession 0001127602-17-012558
Medtronic plc · MDT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Rob Ten Hoedt
Officer — EVP & President EMEA
Period of report
Mar 20, 2017
Accepted (ET)
Mar 21, 2017 · 6:07 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001613103
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Mar 20, 2017 | M | 8,154 | $37.53 | A | 59,392 | D | |
| Ordinary Shares | Mar 20, 2017 | M | 21,129 | $38.81 | A | 80,521 | D | |
| Ordinary Shares | Mar 20, 2017 | M | 10,357 | $62.76 | A | 90,878 | D | |
| Ordinary Shares | Mar 20, 2017 | M | 11,117 | $55.32 | A | 101,995 | D | |
| Ordinary SharesF1,F2 | Mar 20, 2017 | S | 50,757 | $81.5768 | D | 51,238 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $37.53 | Mar 20, 2017 | M | 8,154 | D | — | Aug 2, 2020 | Ordinary Shares | 8,154 | 0 | D |
| Stock Option (Right to Buy)F4 | $38.81 | Mar 20, 2017 | M | 21,129 | D | — | Jul 30, 2022 | Ordinary Shares | 21,129 | 0 | D |
| Stock Option (Right to Buy)F5 | $62.76 | Mar 20, 2017 | M | 10,357 | D | — | Jul 28, 2024 | Ordinary Shares | 10,357 | 11,951 | D |
| Stock Option (Right to Buy)F6 | $55.32 | Mar 20, 2017 | M | 11,117 | D | — | Jul 29, 2023 | Ordinary Shares | 11,117 | 5,514 | D |
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $81.301 to $82.098, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- F2This balance increased by 386 shares due to exempt transactions such as dividend reinvestment.
- F3This option to purchase 8,154 New Medtronic ordinary shares for $37.53 per share, which was fully vested at the effective time of the Merger, was received in the Merger and represents the conversion of 8,154 Medtronic common stock shares for $37.53 per share. This New Medtronic stock option has the same terms and conditions as the original Medtronic stock option.
- F4This option to purchase 21,129 New Medtronic ordinary shares for $38.81per share, which was partially vested at the effective time of the Merger, was received in the Merger and represents the conversion of 21,129 Medtronic common stock shares for $38.81per share. This New Medtronic stock option has the same terms and conditions as the original Medtronic stock option.
- F5This option to purchase 20,714 New Medtronic ordinary shares for $62.76 per share, which was unvested at the effective time of the Merger, was received in the Merger and represents the conversion of 20,714 Medtronic common stock shares for $62.76 per share. This New Medtronic stock option has the same terms and conditions as the original Medtronic stock option.
- F6This option to purchase 14,823 New Medtronic ordinary shares for $55.32 per share, which was partially vested at the effective time of the Merger, was received in the Merger and represents the conversion of 14,823 Medtronic common stock shares for $55.32 per share. This New Medtronic stock option has the same terms and conditions as the original Medtronic stock option.